Application of quantitative real-time reverse transcription-PCR in assessing drug efficacy against the intracellular pathogen Cryptosporidium parvum in vitro
about
Inhibition of Chikungunya Virus Replication by 1-[(2-Methylbenzimidazol-1-yl) Methyl]-2-Oxo-Indolin-3-ylidene] Amino] Thiourea(MBZM-N-IBT)Reprofiled drug targets ancient protozoans: drug discovery for parasitic diarrheal diseasesA screening pipeline for antiparasitic agents targeting cryptosporidium inosine monophosphate dehydrogenasePlant-type trehalose synthetic pathway in cryptosporidium and some other apicomplexansThe Cryptosporidium parvum transcriptome during in vitro developmentCryptosporidium Lactate Dehydrogenase Is Associated with the Parasitophorous Vacuole Membrane and Is a Potential Target for Developing TherapeuticsDetection and quantification of Cryptosporidium in HCT-8 cells and human fecal specimens using real-time polymerase chain reaction.Prodrug activation by Cryptosporidium thymidine kinase.Efficacy of S-adenosylhomocysteine hydrolase inhibitors, D-eritadenine and (S)-DHPA, against the growth of Cryptosporidium parvum in vitro.Novel anti-Cryptosporidium activity of known drugs identified by high-throughput screening against parasite fatty acyl-CoA binding protein (ACBP)In vitro determination of anticryptosporidial activity of phytogenic extracts and compounds.Transcriptome analysis reveals unique metabolic features in the Cryptosporidium parvum Oocysts associated with environmental survival and stressesDrug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growthQuantification of in vitro and in vivo Cryptosporidium parvum infection by using real-time PCR.Genome-wide upstream motif analysis of Cryptosporidium parvum genes clustered by expression profileInvolvement of host cell integrin α2 in Cryptosporidium parvum infection.Quantitative RT-PCR assay for high-throughput screening (HTS) of drugs against the growth of Cryptosporidium parvum in vitro.Differential Gene Expression and Protein Localization of Cryptosporidium parvum Fatty Acyl-CoA Synthetase Isoforms.Inactivation of protozoan parasites in food, water, and environmental systems.Targeting a prokaryotic protein in a eukaryotic pathogen: identification of lead compounds against cryptosporidiosis.Inhibition of apoptosis in Cryptosporidium parvum-infected intestinal epithelial cells is dependent on survivin.Human primary intestinal epithelial cells as an improved in vitro model for Cryptosporidium parvum infection.Treatment of parasitic diarrhea in HIV-infected patients.Amelioration of Cryptosporidium parvum infection in vitro and in vivo by targeting parasite fatty acyl-coenzyme A synthetases.Novel Bioengineered Three-Dimensional Human Intestinal Model for Long-Term Infection of Cryptosporidium parvum.Susceptibility Testing of Medically Important Parasites.Efficacy of ginkgolic acids against Cryptosporidium andersoni in cell culture.Stress-induced Hsp70 gene expression and inactivation of Cryptosporidium parvum oocysts by chlorine-based oxidants.Preliminary Characterization of MEDLE-2, a Protein Potentially Involved in the Invasion of Cryptosporidium parvum.Aged HCT-8 cell monolayers support Cryptosporidium parvum infection.Characterization of Host Cell Mutants Significantly Resistant to Cryptosporidium parvum Infection.A unique hexokinase in Cryptosporidium parvum, an apicomplexan pathogen lacking the Krebs cycle and oxidative phosphorylation.Discovery of ebselen as an inhibitor of Cryptosporidium parvum glucose-6-phosphate isomerase (CpGPI) by high-throughput screening of existing drugs.Molecular and biochemical characterization of Eimeria tenella hexokinase.
P2860
Q24289284-23937E42-4926-4CF8-83FC-C1035CC6685FQ27003233-06079751-7287-4103-9684-14436FAD67F4Q28475058-98172189-02D6-4870-BA0C-4CAA4BEEFFCFQ28475422-D785BDB6-74FF-4B9A-B517-A578FD174E18Q28481508-57E3AA63-02F0-47C7-AD91-AB31618965C5Q28550913-9408DA29-A98D-4FAC-93E1-32A9E97943CEQ30443537-644802A8-B94B-4068-82D1-F2672BB858DBQ33855150-BDE29279-CC8A-4BBC-9479-251ED37EC6C6Q34039880-EDB1363F-D804-49B5-9C79-4E73AA8651D5Q34100267-9090A714-CD70-407D-8445-2E92495EF6B9Q34141383-511F2FC2-042A-40F6-835B-B1B78D732479Q34484657-513F3555-1942-4087-BDF8-7EF008D849FBQ34574121-F804771B-D321-4D85-9B43-D391BB046D19Q34720875-A5153A6B-352F-4EC8-AF15-E849A9C3C77BQ34878212-DD3A888F-151C-4C2A-9853-7C612BACE2E6Q35944070-77A51413-A770-4331-AACD-A5F992AB023CQ36098066-D7D92943-8137-4C75-9469-E33EC3698854Q36642424-CD43E3FA-EA0A-4637-915A-47C6D78B0498Q36668014-AB0685A5-F9B8-41D2-B2B4-BA073BC1F147Q36740182-49C09207-94E8-474F-8BC4-6E27D6D712AFQ36804184-9CEF7723-79B5-41A7-8920-46E51CDC69ADQ36911475-454EFA34-0B6E-433B-B48D-1B55C9842C60Q37202848-995103EC-A89D-4C3A-874C-54579469E941Q37671934-375B7576-5DED-4F86-B272-64650CE667C4Q38722957-E632E64B-A228-48AE-BF9A-4EEE59AAF138Q39020376-8B9A4BC9-2190-43D2-B33F-68FF27FB9041Q39545463-6C4AA443-3ED6-47F9-BD09-97F1F6321834Q39607184-6B312425-1738-41D2-B6A0-05A5E10BF4EDQ40044929-27DABEEF-CC59-4D12-A3F2-037A13A4B4CBQ40068500-3AEDB15F-EECC-470F-ADEC-51226527162EQ40241688-26194C14-FB97-4BDB-8430-1D59284435F4Q41741437-CDF578F5-D53B-4F58-A07E-868B597368FCQ50136314-5E47C5AB-E208-4056-9AA5-41ED1CA7C6FEQ54195824-B0611C6A-E6AD-444A-91BD-D9C831E3255C
P2860
Application of quantitative real-time reverse transcription-PCR in assessing drug efficacy against the intracellular pathogen Cryptosporidium parvum in vitro
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Application of quantitative re ...... ryptosporidium parvum in vitro
@ast
Application of quantitative re ...... ryptosporidium parvum in vitro
@en
Application of quantitative re ...... ryptosporidium parvum in vitro
@nl
type
label
Application of quantitative re ...... ryptosporidium parvum in vitro
@ast
Application of quantitative re ...... ryptosporidium parvum in vitro
@en
Application of quantitative re ...... ryptosporidium parvum in vitro
@nl
prefLabel
Application of quantitative re ...... ryptosporidium parvum in vitro
@ast
Application of quantitative re ...... ryptosporidium parvum in vitro
@en
Application of quantitative re ...... ryptosporidium parvum in vitro
@nl
P2093
P2860
P1476
Application of quantitative re ...... ryptosporidium parvum in vitro
@en
P2093
Keith M Woods
Steve J Upton
Xiaomin Cai
P2860
P304
P356
10.1128/AAC.49.11.4437-4442.2005
P407
P577
2005-11-01T00:00:00Z